The Solutions to Empower Patients (STEP) Program™ continues to help nonprofit organizations deliver new solutions to address unmet patient needs This year’s focus is on addressing some of the most pressing issues in the sickle cell disease (SCD) community Novartis has announced that five nonprofit organizations will receive a total of nearly $250,000 in funding …

Novartis Awards $250k grant to support SCD initiativesRead More »

Crizanlizumab is a monthly infusion under development to prevent pain crises (also called vaso-occlusive crises, or VOCs) in patients with sickle cell disease  Sickle cell VOCs, which are triggered by multi-cell adhesion or clusters of cells that block or reduce blood flow, are associated with increased morbidity and mortality1 FDA filing of crizanlizumab anticipated in …

Crizanlizumab receives FDA Breakthrough Therapy designation for the prevention of vaso-occlusive crisesRead More »